The TGA has released a public consultation, closing 19 December 2022, seeking views on whether the dual naming of certain ingredients should end on 30 April 2023.

In relation to listed complementary medicines, only sponsors of medicines containing mecobalamin (comethylcobalamin) are affected. 

This technical alert provides information for affected sponsors of mecobalamin (comethylcobalamin), including CMA’s draft position and details on how to respond to the consultation.